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Abstract 
 
We extend a prior analysis on the relation between poverty and cancer incidence in a sample of 
2.90 million cancers diagnosed in 16 U.S. states plus Los Angeles over the 2005-2009 period by 
additionally considering stage at diagnosis. Recognizing that higher relative disparities are often 
found among less-common cancer sites, our analysis incorporated both relative and absolute 
measures of disparities. Fourteen of the 21 cancer sites analyzed were found to have significant 
variation by stage; in each instance, diagnosis at distant stage was more likely among residents of 
high-poverty areas. If the incidence rates found in the lowest-poverty areas for these 21 cancer 
sites were applied to the entire country, 18,000 fewer distant-stage diagnoses per year would be 
expected, a reduction of 8%. Conversely, 49,000 additional local-stage diagnoses per year would 
be expected, an increase of 4%. These figures, strongly influenced by the most common sites of 
prostate and female breast, speak to the trade-offs inherent in cancer screening. Integrating the 
type of analysis presented here into routine cancer surveillance activities would permit a more 
complete understanding of the dynamic nature of the relationship between socioeconomic status 
and cancer incidence.  
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Introduction 
 
In order to better understand and ameliorate cancer disparities, it is essential to track the 
relationship between cancer incidence and socioeconomic status (SES).1,2 A recent United 
States-based study found that nearly all of the most common anatomic sites of cancer displayed a 
significant relationship with poverty, with the rates differing by as much as a factor of two 
between the poorest and most affluent groups.3 A shortcoming of this study is that it did not 
consider stage at diagnosis, which itself often correlates with SES. Specifically, worse stage 
distributions (that is, a tendency toward more advanced stage at diagnosis) are often 
characteristic of poorer populations. To characterize a disease such as prostate cancer as 
“affluent”4 is misleading because a large majority of prostate cancers are diagnosed at early 
stage. Late-stage prostate cancer, in contrast, is more characteristic of poorer populations,5 but 
this detail is lost when all prostate cancers are grouped together. Here we make use of the same 
data set used in the recent US study to measure the role of stage in the cancer incidence-poverty 
relationship. 
 
A novel element of our analysis is that we report both absolute and relative measures of SES 
disparities. Cancer sites previously identified as having the largest disparities are, in many cases, 
quite rare in absolute terms (as with Kaposi sarcoma and larynx, for example), making them less 
amenable to high-impact public health interventions, except insofar as they share risk factors 
with more common cancer types. There have been numerous calls in recent years for the 
inclusion of both absolute and relative measures in published research6-9, but these calls have not 
been widely heeded: a recent review found only 7% of publications reported an absolute 
measure.10  
  
Material and Methods  
 
We used a data file containing 2.90 million incident cancers diagnosed in 16 participating US 
states (Arizona, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Iowa, Louisiana, 
Minnesota, New Hampshire, New Jersey, New York, Texas, Utah, West Virginia) plus Los 
Angeles County, California between 2005 and 2009.3 Together, these areas include about 42% of 
the United States population for this time period and collectively have a poverty rate of 13.5%, 
similar to the national average of 13.3% as measured by the American Community Survey 
(ACS) during these same years. Cancer cases in the central tumor registries of these states were 
geocoded to the census tract and assigned to one of four categories based on the percentage of 
households below the poverty threshold as measured by the ACS: 0-<5%, 5-<10%, 10-<20%, 
and over 20%. These categories have been widely used in cancer surveillance and 
epidemiological research generally and have been shown to be a simple and effective measure of 
SES.11-12 The 20% poverty threshold is also used as a criteria for some federal aid programs.13 
The categories also conveniently divide the nation into four roughly equal parts, ranging from 22 
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to 30 percent of the population. Census tracts are relatively homogeneous and stable geographic 
units with an average population of about 4,000. 
 
Using poisson regression, we modeled the cancer rate for each anatomic site of cancer by stage 
for each of the four poverty categories, using a widely used list of sites developed by the 
National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) program14, after 
excluding those cancer sites which are not staged or rarely staged (myeloma, leukemia, and 
miscellaneous sites), leaving 2.72 million tumors for analysis. We focused our analysis on the 21 
most common cancer sites that collectively account for 97% of all stageable tumors. These sites 
and their shorthand names used subsequently in this paper are given in Table 1. Sites less 
common than these had stage-specific rates with very wide confidence intervals and were not 
informative. Stage was classified using the derived SEER Summary Stage 2000 staging system 
into local, regional, distant and unknown.15 The models estimated cancer rates for each site as a 
function of the population size, age (5-year age groups through 85+), sex, race/ethnicity (white, 
black, Hispanic, American Indian/Alaska Native, Asian and Pacific Islander), and poverty 
category. The populations were obtained from a custom file developed by Woods & Poole, Inc. 
for the use of the SEER program that has been described elsewhere.3,16 We additionally modeled 
the cancer rates for three site groupings: all stageable sites combined, tobacco-related sites (oral, 
esophagus, larynx, lung, and bladder), and HPV-related sites (penis, vagina, vulva, cervix, anus, 
and the oral cancer subsites nasopharynx, oropharynx, hypopharynx, and tonsil). Breast cancer 
was limited to females only; male breast cancer was included in all stageable sites combined. 
The cancer counts and populations used in the models are available in an online data repository 
associated with this project.17  
 
We computed the relative risk of the highest poverty category to the lowest poverty category by 
stage for each site and site grouping. In addition to this relative measure of disparity, we also 
computed an absolute measure, consisting of a comparison of the total number of cases by 
site/stage with the total number predicted by the model after discounting the effects of poverty 
(that is, if the parameter estimates for all variables in the model for the lowest poverty category 
were applied to the age, race, and sex counts and populations for the other three poverty 
categories). To make this number more interpretable, we converted the counts from five-year 
totals based on 42% of the US population to single-year totals based on the entire US population, 
assuming that our sample was representative of the nation as a whole. That is, we took the five-
year totals, divided by five, then divided by 0.42.  
 
 
Results 
 
The relative measure of disparity is shown in Figure 1. For clarity, only local and distant stage 
are depicted here; values for all stages and sites are available in the project data repository.17 For 
14 of the 21 sites (larynx, cervix, oral, lung, prostate, kidney, bladder, colorectal, female breast, 
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testis, uterus, melanoma, thyroid, NHL), as well as for HPV-related, tobacco-related, and all 
stageable sites combined, diagnosis at distant stage was more strongly associated with poverty 
than diagnosis at early stage, as determined by the presence of non-overlapping confidence 
intervals in Figure 1. For 7 sites (liver, esophagus, stomach, brain, HL, pancreas, ovary), there 
was no significant difference in stage distribution by poverty. There were no sites where 
diagnosis at local stage was more strongly associated with poverty. 
 
Of the 14 sites with a stage disparity by poverty, 7 (prostate, kidney, bladder, female breast, 
testis, uterus, and melanoma) had a more pronounced form, with higher-poverty areas having 
both a significantly elevated risk of distant-stage diagnosis and a significantly diminished risk of 
early-stage diagnosis. For example, for prostate cancer, the relative risk of diagnosis at distant 
stage was 1.27 times higher in the highest poverty category than in the lowest poverty category 
(95% confidence interval: 1.20-1.34), while the relative risk of early stage prostate cancer was 
0.77 (0.76-0.78). This characteristic was also true of tobacco-related cancers and all cancers 
combined. 
 
The absolute measure of disparity is presented in Figure 2 (the raw counts used to develop this 
figure are available in the project data repository).17 Note that the scale in the top row was 
compressed by a factor of 2.5 in order to fit all sites onto a single page. The figure shows that 
discounting the effects of poverty would result in large increases in the numbers of local and 
regional stage prostate and breast cancers, as well as early stage bladder, melanoma, and thyroid 
cancers. The only major decreases would be found among regional, distant, and unstaged lung 
cancers. For most sites, the absolute changes for all stages would be small, even though they may 
be large in relative terms. For example, late-stage oral cancer counts would decrease by about 
1,000, barely discernable in the figure but representing a decrease of 22%.  
 
Discounting poverty would result in an absolute reduction in cancer at local, regional, and distant 
stage for seven sites (lung, colorectal, oral, liver, esophagus, cervix, larynx). For prostate, breast, 
and kidney there would be a reduction in distant stage tumors but an even larger increase in the 
number of local-stage tumors. For six sites, there would be an increase in local-stage tumors and 
almost no change in the number of distant stage tumors (bladder, melanoma, uterus, thyroid, 
brain, testis). Ovary, HL, and NHL would see an increase in tumors at all stages. Pancreas would 
have small increases in regional and distant stage, and stomach would remain essentially 
unchanged.  
 
For these 21 sites combined, discounting poverty would be expected to result in nearly 46,000 
additional tumors, or a 4% increase. Tumors diagnosed at early stage would increase by 64,000 
(10%) and at regional stage by 3,000 (1%). Tumors diagnosed at distant stage would decrease by 
18,000 (8%) and at unknown stage by 4,000 (3%).  
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Discussion 
We found that, in general, high poverty areas tended to have worse stage distributions than low 
poverty areas. This was apparent whether the data were presented on a relative scale (Figure 1) 
or absolute scale (Figure 2), though the relative scale may exaggerate the apparent importance of 
poverty by presenting all cancer sites on a seemingly equal basis. If we consider only the four 
most common cancer sites (prostate, breast, lung, and colorectal) that account for roughly half of 
all cancers, for two of these (lung and colorectal) there would be an unqualified benefit 
accompanying any reduction in poverty, as the numbers of tumors at every stage would be 
expected to diminish. For the other two (breast and prostate), we would expect a tradeoff 
between a modest reduction in distant-stage diagnoses and a much larger number of local-stage 
diagnoses. This resembles the tradeoff seen with certain modes of cancer screening, where each 
probable life saved (that is, each late-stage cancer detected earlier) must be balanced against a 
larger number of lives harmed (that is, clinically insignificant early-stage cancer or pre-cancers 
that need not have been detected at all).18 Notably, for the three sites most often diagnosed at 
distant stage (ovary and the two lymphomas), poverty appeared to be protective. Each of these 
sites are difficult to detect at an early stage, and it appears that for these sites this is true 
irrespective of SES.  
The generally worse stage distributions seen in areas with the highest poverty rates would be 
expected to translate into higher cancer mortality rates in these areas. Unfortunately, we were not 
able to measure mortality directly because geocoded vital statistics data at the national level are 
not presently available at the census tract level. Even so, higher mortality rates can reasonably be 
inferred from the dramatic differences in survival by stage seen for nearly all cancer sites. For 
example, the 5-year relative survival for local-stage prostate cancer is at least 100% (meaning 
those with this diagnosis actually tend to outlive their similarly-aged counterparts without 
prostate cancer), while distant-stage is 28%.19 For breast cancer, the corresponding values are 
99% and 26%, and for lung cancer, 55% and 4%.20,21 In addition, recent work by Singh et al. at 
the county level found that cancer mortality in the lowest-income decile was higher than that in 
the highest-income decile for all cancers combined and for lung, colorectal, prostate, breast, and 
cervix.22  
Cancer sites that would be expected to have more local-stage diagnoses and the same or fewer 
distant-stage diagnoses after discounting poverty overlap substantially with cancer sites known 
to be overdiagnosed, or detected in the absence of symptoms and unlikely or contribute to 
death.23 Among these sites are prostate, breast, kidney, thyroid, and melanoma. For these sites, 
the “better” stage distribution found in the most affluent group does not necessarily constitute an 
advantage. For example, the rates of early-stage thyroid cancer are more than 30% higher in the 
most affluent group compared with the poorest group, while the rates of distant-stage thyroid 
cancer are nearly identical in both groups. To discount the effects of poverty here would only 
result in an increase in the number of early (and regional) stage diagnoses. This relationship can 
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be inferred from Figure 1, as the relative risk of distant-stage thyroid cancer is close to 1, with 
wide confidence intervals indicating rarity, while local-stage thyroid cancer is centered below 
0.7, with narrow confidence intervals indicating it is more common. Figure 2, however, shows 
the relationship much more directly. 
 
We included unknown stage in Figure 2 as an illustration of how even a data element as 
fundamental to cancer surveillance as stage is not always well-collected - often the number of 
unknown stage equal or exceed the number of regional or distant stage. For most sites, the 
expected change in the number of cases with unknown stage after discounting the effects of 
poverty tracks the expected change in the most frequent stage. Pancreas is one exception - even 
as the number of cases would increase by 5% after discounting poverty, the number with 
unknown stage would decrease by 7%, suggesting the presence of a SES-based disparity in data 
quality for this site.   
 
We note that our findings are specific to the period 2005-2009, and that the dynamic nature of 
cancer screening and prevention efforts and behavioral risk factors mean that the results would 
not necessarily apply to the current year. For example, local-stage prostate cancer incidence in 
the United States dropped by 25% between 2011 and 2012 following the United States 
Preventive Services Task Force recommendation against PSA testing.24 Were we to repeat our 
analysis with 2012 data, we would expect to find the projected number of additional local-stage 
prostate cancer cases diagnosed after discounting poverty to diminish considerably, reducing or 
perhaps even eliminating the SES disparity for local disease, while leaving the disparity for 
distant disease intact. Similarly, the introduction of vaccinations against HPV-related cancers are 
expected to exert substantial downward pressure on the absolute numbers of these cancers, even 
as relative disparities may rise, at least temporarily, as those at greater risk for the disease may be 
less likely to receive the vaccinations.25 The dynamic nature of the cancer-SES relationship 
argues in favor of it becoming a routine part of national cancer surveillance rather than the 
subject of an occasional focused investigation such as this one.  
 
Overall, these findings support the general conclusion that poorer populations are more likely to 
die of cancer while wealthier populations are more likely to die with it. The poor are not simply 
at higher risk of more fatal cancers, but also at higher risk of being diagnosed with more fatal 
forms of less-fatal cancers. Specifically, our results suggest that poverty contributes to an 
additional 18,000 distant-stage cancers in the United States each year while protecting against 
64,000 early-stage cancers. Reducing these disparities will require both improvements in primary 
prevention and improvements in the sensitivity of cancer screening. 
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Table 1. Included cancer sites. 
  
Cancer site name14  Short name used throughout this paper 
Oral cavity and pharynx Oral 
Esophagus Esophagus 
Stomach Stomach 
Colon and rectum Colorectal 
Liver and intrahepatic bile duct Liver 
Pancreas Pancreas 
Larynx Larynx 
Lung and bronchus Lung 
Melanoma of the skin Melanoma 
Breast Breast 
Cervix Uteri Cervix 
Corpus and uterus, NOS Uterus 
Ovary Ovary 
Prostate Prostate 
Testis Testis 
Urinary bladder Bladder 
Kidney and renal pelvis Kidney 
Brain and other nervous system Brain 
Thyroid Thyroid 
Hodgkin lymphoma HL 
Non-Hodgkin lymphoma NHL 
  
 
 
 
Cervix
Prostate
Testis
Thyroid
Melanoma
1.0
Larynx
Female breast
0.5 1.5 2.0
1.00.5 1.5 2.0
HPV-related 
Liver 
Lung 
Oral 
Tobacco-related 
Esophagus
Stomach
Colorectal
Kidney 
Pancreas
All stageable cancers
Ovary
Uterus
Brain 
NHL
Bladder
HL
2.5 3.0
2.5 3.0
Distant
Local
3.2
Figure 1. Relative risk of cancer incidence between highest (over 20%) and lowest (<5%) 
poverty category, by site and stage, United States, 2005-2009. 
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Figure 2. Estimated number of newly diagnosed cancers per year (in thousands), by site and 
stage, United States, 2005-2009, showing the influence of poverty. 
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